The network of immunosuppressive pathways in glioblastoma by Mangani, Davide et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
The network of immunosuppressive pathways in glioblastoma
Mangani, Davide; Weller, Michael; Roth, Patrick
DOI: https://doi.org/10.1016/j.bcp.2016.12.011
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-141054
Accepted Version
 
 
Originally published at:
Mangani, Davide; Weller, Michael; Roth, Patrick (2017). The network of immunosuppressive pathways
in glioblastoma. Biochemical Pharmacology, 130:1-9.
DOI: https://doi.org/10.1016/j.bcp.2016.12.011
1 
 
The network of immunosuppressive pathways in glioblastoma 
 
Davide Mangani1, Michael Weller1,2, Patrick Roth1,2  
 
1Laboratory of Molecular Neuro-Oncology, Department of Neurology and Brain 
Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland; 
2Center for Neuroscience, University of Zurich, Zurich, Switzerland 
 
Correspondence: Dr. Patrick Roth, Department of Neurology, University Hospital, 
Frauenklinikstrasse 26, 8091 Zurich, Switzerland, Tel.: +41 (0)44 255 5511, Fax: +41 
(0)44 255 4380, E-mail: patrick.roth@usz.ch 
 
Running Title: Glioblastoma-mediated immunosuppression 
 
Word count: 4150  
Figures: 3 
 
Abbreviations: antigen-presenting cells (APC); blood brain barrier (BBB); colony 
stimulating factor-1 receptor (CSF-1R); cytotoxic T lymphocyte antigen 4 (CTLA-4); 
deep cervical lymph node (dcLN); dendritic cells (DC); forkhead box P3 (FoxP3); 
glioblastoma (GBM); growth and differentiation factor-15 (GDF-15); hypoxia inducible 
factor (HIF)-1α; interferon (IFN); indoleamine-2,3-dioxygenase (IDO); induced Treg 
(iTreg); interleukin-2 receptor alpha chain (CD25); lectin-like transcript-1 (LLT-1); 
major histocompatibility complex (MHC); matrix metalloproteinase (MMP); myeloid-
derived suppressor cells (MDSC); natural killer (NK); natural Treg (nTreg); nitric oxide 
(NO); programmed cell death 1 (PD-1); PD ligand-1 (PD-L1); regeneration and 
tolerance factor (RTF); regulatory T cells (Treg); transforming growth factor-β (TGF-
β); tryptophan-2,3-dioxygenase (TDO); tumor-associated macrophages (TAM); 
vascular endothelial growth factor (VEGF) 
  
2 
 
Abstract 
 
Glioblastoma remains a fatal tumor despite increased knowledge regarding the 
complex signalling pathways that drive this devastating disease. Recently, 
immunotherapeutic approaches have shown remarkable and durable responses in 
various cancers including metastatic melanoma and advanced non-small cell lung 
cancer. So far, it remains unclear whether these immunotherapeutics may also work 
against glioblastoma and other tumors residing in the central nervous system. It is 
well known that patients with glioblastoma suffer from profound local 
immunosuppression that represents the major hurdle to overcome in the context of 
immunotherapy. Several studies have demonstrated that this immunosuppressive 
phenotype is orchestrated by glioma-derived membrane-bound and soluble factors 
as well as the particular microenvironment within the brain. Here, we discuss the 
molecular and cellular pathways involved in glioblastoma-mediated inhibition of the 
immune system and highlight possible treatment approaches aiming at reinvigorating 
anti-tumor immune responses. 
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1. Introduction 
 
Glioblastoma is the most common and deadly primary malignant brain tumor in adults 
[1]. Despite maximal safe surgery, radio- and chemotherapy, the prognosis remains 
dismal with a median survival around 16 months within clinical trial populations [2]. 
Great promises held by targeted treatments directed against vascular endothelial 
growth factor (VEGF) or specific integrins were not fulfilled since these drugs failed to 
prolong overall survival in randomized clinical trials [3-5]. Hence, new therapeutic 
modalities are urgently needed. Immunotherapy has been regarded a promising 
treatment option for decades, however, without making significant progress. 
However, the therapeutic success achieved by “immune checkpoint inhibitors” in 
several tumor entities such as metastatic melanoma and non-small cell lung cancer 
with so far unseen response rates, paved the road for a renewed interest in exploring 
immunotherapeutic strategies also against glioblastoma [6-8]. 
Most therapeutic strategies employing the immune system are based on the 
consideration that T cells can recognize and respond against genetic and cellular 
alterations which occur during cancer development and progression [9]. Preclinical 
data from experiments using various methylcholanthrene-induced tumors 
demonstrated that knock-out mice lacking either components of the interferon (IFN)-γ 
pathway or the perforin gene are more susceptible to tumor formation [10, 11]. 
Subsequent studies proved the existence of tumor-specific T cells directed against 
mutated or overexpressed proteins confirming the presence of anti-tumor immune 
responses [12]. However, selective pressure on tumor cells by the immune system 
may lead to the emergence of immune-edited clones that escape recognition and 
ultimately grow undisturbed [13].  
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GBM is peculiar for its ability to escape from immune surveillance and two major 
challenges represent a major obstacle for the successful administration of 
immunotherapies: the tumor location in the brain which comprises an 
immunoprivileged microenvironment as well as the presence of several glioma-
derived mechanisms of active immunosuppression. 
In this review article, we illustrate the pathways that are mainly involved in mediating 
glioblastoma-associated immunosuppression and therapeutic strategies which aim at 
reinvigorating immune responses against the tumor. 
 
 
2. Blood brain barrier and immunological routes to the brain 
 
A first hurdle to overcome in the context of immunotherapies for brain tumors is 
represented by the tumor location within the CNS. The presence of the blood brain 
barrier (BBB) and the absence of classical lymphatic vessels are two major issues 
that may hamper the successful administration of any immunotherapy. The BBB is a 
cellular barrier formed by specialized brain endothelial cells, pericytes and astrocytes, 
which regulates the ionic composition of the brain thereby maintaining appropriate 
neuronal function by blocking the entrance of unwanted and possibly neurotoxic 
molecules. The latter property relies on the presence of several ATP-binding cassette 
(ABC) transporters, that actively export molecules and drugs out of the brain [14]. 
The BBB also regulates the entry of immune cells to the CNS. Under physiological 
conditions, only few immune cells are present in the brain parenchyma, whereas 
various pathological conditions result in disruption of the BBB which then becomes 
more permeable to immune cell entry [15-17].  Substantial work has shown that 
antigens released within the CNS are drained towards peripheral lymphoid tissues 
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and can be presented by antigen-presenting cells (APC) to naïve T cells, which can 
subsequently be activated and upregulate the expression of α4 and β1 integrins [18, 
19]. Only when expressing these integrins, lymphocytes can interact with vascular 
cell adhesion molecule (VCAM)-1 expressed on the cerebral endothelium and pass 
across the BBB. Immune cell infiltration has been found in glioblastoma, however, to 
a variable extent [20-22]. 
Despite being partially disrupted during tumor progression, intact zones of the BBB 
may protect tumor cells invading the normal brain parenchyma from drug delivery, 
representing a possible explanation for the re-iterated failure of various systemic 
therapies in GBM and other brain tumors [23-25]. Therefore, it is unlikely that 
antibodies used as therapeutics for the targeting of  immunomodulatory molecules, 
can reach all parts of the tumor in the brain and exert any effect unless they interact 
with target molecules in the periphery [26]. Of note, attempts to circumvent or block 
BBB drug-efflux activity to improve standard and targeted GBM treatments are 
currently being investigated [27]. 
Since it has long been believed that a classical lymphatic drainage system is absent 
in the CNS, it has been assumed that brain immune-surveillance occurs mainly in the 
meningeal compartment. Yet, recent evidence has questioned this long-held belief 
and shed new light on immune cell trafficking between the brain and extracranial 
sites. Indeed, two laboratories have independently found a dural lymphatic vascular 
system that drains fluids, macromolecules and immune cells from the cerebrospinal 
fluid, and is connected to the deep cervical lymph-nodes (dcLN) in rodent models [28, 
29]. Although further experiments are required to finally confirm the functional 
trafficking of T cells to and from the human brain, the existence of a cellular route is 
further supported by single reports suggesting dcLN metastasis in primary brain 
tumors [30]. The discovery of the dural lymphatic route, along with the recently 
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described glymphatic system - a cellular pathway which facilitates CSF drainage and 
clearance of potentially toxic metabolites and unfolded proteins such as β-amyloid 
and tau protein into the brain parenchyma – suggests that the brain cannot be seen 
as an immune-privileged organ anymore but rather an immune-distinct site which is 
still accessible for immunotherapeutic approaches [31].   
 
 
3. Mechanisms of immunosuppression in glioblastoma 
 
3.1 Immunosuppressive immune cell subsets  
 
3.1.1 Regulatory T cells 
 
Regulatory T cells (Treg) account for 5-10% of all circulating CD4+ T cells and are 
key modulators of the immune system maintaining tolerance to self and host antigens 
and inhibiting autoimmunity through resolution of tissue inflammation [32]. This T cell 
subset is characterized by the constitutive expression of the nuclear transcription 
factor forkhead box P3 (FoxP3), interleukin-2 receptor alpha chain (CD25), cytotoxic 
T lymphocyte antigen 4 (CTLA-4) and the glucocorticoid-induced tumor necrosis 
factor (TNF) receptor (GITR) [33]. Two main types of Treg exist: natural Treg (nTreg) 
which have developed in the thymus and induced Treg (iTreg) arising from FoxP3 
induction in conventional CD4+ T cells exposed to an immunosuppressive 
microenvironment. Despite marked lymphopenia, the Treg fraction in the peripheral 
blood and tumor specimens of glioma patients is increased and correlates with tumor 
grade and poor prognosis [34-36]. However, Treg presence in the blood or tumor as 
negative prognostic factor remains controversial since low percentage and no impact 
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on survival was observed in several other studies [20, 37, 38]. Discrepancies may be 
due to the existence of different Treg subtypes that can only be dissected by high-
dimensional analyses and not only based on FoxP3 staining. In experimental models, 
glioma-infiltrating Treg are mostly thymus-derived nTreg as tumor entrance is 
drastically impaired in previously thymectomized mice [39]. This finding supports the 
idea that the glioma microenvironment efficiently recruits nTreg from the periphery, 
mainly through the chemokine/chemoreceptor axis C-C motif chemokine ligand 22 
(CCL22)-C-C motif chemokine receptor 4 (CCR4), rather than switching conventional 
cells into iTreg [40]. In a transgenic mouse model of spontaneous astrocytoma it was 
observed that in early stage mice before symptom onset, CD4+ and CD8+ T cells 
were primarily recruited to the tumor with a significant proportion being CD4+ CD25+ 
T cells which comprise Treg [41]. To date, efficient targeting of the Treg population 
has been achieved with monoclonal antibodies (mAb) directed against CD25. 
Treatment of SMA-560 glioma-bearing VM/Dk mice with anti-CD25 mAb resulted in 
functional inactivation of Treg and increased anti-glioma immunity [34]. Furthermore, 
a humanized antibody against CD25 showed a good safety profile in patients with 
GBM and warrants further investigation in clinical trials [42]. A reduction of Treg 
infiltration in the tumor microenvironment may also be achieved indirectly by other 
therapeutic strategies. A vaccine generated by dendritic cells (DC) pulsed with tumor 
cell lysate induced a shift in the brain tumor immune cell infiltrate from Treg to T 
effector cells [43]. Of note, only vaccines derived from GL-261 murine glioma cells 
pre-treated with a combination of hypericin and light irradiation induced changes in 
the infiltrating T cell repertoire. This may be due to the fact that this treatment is 
supposed to elicit immunogenic cell death, which ultimately fosters anti-tumor 
responses [44].  Similarly, inhibition of transforming growth factor (TGF)-β signalling 
decreased the level of brain tumor-infiltrating Treg most likely as a consequence of 
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reduced trafficking from the periphery [45]. Data published by Lowther and 
colleagues suggest that a dysfunctional Treg population, marked by high expression 
of programmed cell death 1 (PD-1), has impaired suppressive activity and secretes 
high levels of IFN-γ [46]. This finding follows the discovery that Treg cells may drive 
tissue repair through the secretion of amphiregulin in response to inflammatory 
signals [47, 48]. Altogether, these observations reflect a broader role played by these 
cells in tissue inflammation and homeostasis, and challenge the view of a sole direct 
suppressive effect on antitumoral responses. 
 
3.1.2 Tumor associated microglia/macrophages and myeloid-derived 
suppressor cells 
 
Microglia and macrophage cells are the dominant immune infiltrate in gliomas and 
have been extensively studied for their key role in tumor pathogenesis [49, 50]. They 
can constitute up to 12% of the tumor mass and accumulation of these cells 
correlates with glioma tumor grade [51, 52]. These cells are part of the tumor mass 
and re-wired to secrete pro-tumorigenic factors. 
Classically, microglial cells and macrophages have been distinguished by the cell 
surface marker CD45 with microglia being CD45low and macrophages CD45high. In 
GBM, the CD45high population represents the largest fraction, even though microglial 
cells can upregulate CD45 levels during inflammatory conditions precluding a definite 
differentiation [53, 54]. To date, there are no generally accepted markers to 
distinguish these two cell populations that are characterized by a broad phenotypic 
plasticity. In general, two main phenotypes of macrophages and microglia exist: 
classically activated M1 cells, which have a marked effector activity against tumor 
cells and produce high amounts of pro-inflammatory cytokines, and alternatively 
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activated M2 cells, which tune down immune activation promoting tissue remodelling 
and repair.  Notably, M1 and M2 cells represent only the extreme opposite of a 
continuous phenotypic spectrum [55]. Remarkably, this paradigm has been 
challenged by recent studies and the existence of these two polarized phenotypes 
has to be carefully reassessed in the future [56]. In GBM, a high percentage of tumor-
associated macrophages (TAM) displays an immunosuppressive M2 phenotype that 
is characterized by the secretion of various molecules such as TGF-β, VEGF, 
epithelial growth factor (EGF), matrix metalloproteinase (MMP)-2 and MMP-9, which 
can promote tumor cell immune evasion, invasion, proliferation and angiogenesis 
(see below for details) [57-62]. Colony stimulating factor-1 receptor (CSF-1R) is 
expressed on several myeloid compartment cells. Binding of CSF-1 ligand promotes 
macrophage differentiation and survival, and is associated with sustained pro-
tumorigenic functions mediated by this cell population. Targeting CSF-1R increased 
the survival of glioma-bearing mice through re-polarization of macrophages to a pro-
inflammatory M1 phenotype [63]. 
Myeloid-derived suppressor cells (MDSC) represent another cell population with 
immunosuppressive properties. This immature myeloid subpopulation is recruited 
from the bone marrow and exerts inhibiting effects on cytotoxic T cells through nitric 
oxide (NO) production as demonstrated in a rat glioma model. Their presence is 
associated with an overall reduced number of tumor-infiltrating lymphocytes in murine 
and human gliomas [64, 65]. MDSC recruitment and function in the tumor is mainly 
driven by hypoxia, a key characteristic of glioblastomas [66]. In this regard, Du and 
colleagues demonstrated that hypoxia-driven hypoxia inducible factor (HIF)-1α 
expression induces the influx of MDSC to the tumor site which, in turn, enhances 
tumor angiogenesis and invasion [67]. Noman et al showed that HIF-1α has a binding 
site in the promoter of the programmed cell death ligand (PD-L)1 gene [68]. Hence, 
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HIF-1α upregulation may directly induce PD-L1 protein expression in tumor-infiltrating 
MDSC exposed to hypoxic conditions linking the suppressive function of these cells 
to the PD-1 pathway (see below). Besides, the immunosuppressive activity of both 
TAM and MDSC is directly fostered by a population of tumor cells with stem cell 
characteristic, also known as glioma-initiating cells, through the release of soluble 
growth and differentiation factor (GDF)-15, TGF-β1 and macrophage migration 
inhibitory factor (MIF) [69, 70]. In summary, myeloid compartment-derived cells which 
are present in glioblastomas have overlapping functions and intrinsic phenotypic 
plasticity. Furthermore, technical limitations regarding cell fate mapping as well as the 
lack of a commonly accepted nomenclature represent important issues that need to 
be addressed for an improved understanding of the functional role of these cells in 
the immunology of glioblastoma.  
 
3.2 Glioma cell-derived secreted immunosuppressive factors 
 
Glioma cells contribute to the immunosuppressive microenvironment through the 
secretion of various soluble factors (Figure 1). Discovered as glioblastoma derived T 
cell suppressor factor (GsT) because of its ability to impair interleukin (IL)-2-mediated 
T cell survival, TGF-β2 was among the first identified immunosuppressive molecules 
released by glioma cells [71]. Three TGF-β ligand isoforms exist and are expressed 
by glioma cells [72]. To date, mainly TGF-β1 and -β2 have been described as 
modulators of immune cell function in the tumor micromilieu [73]. 
In the presence of TGF-β, CD4+ T cells up-regulate FoxP3 and differentiate into Treg 
cells. Furthermore, CD8+ effector T cells are profoundly impaired by TGF-β through 
activation of a repressive SMAD/ATF1-mediated transcriptional program, which 
inhibits the expression of several genes such as IFN-γ and granzyme B which are 
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required for the generation of a powerful anti-tumor immune response [74-76]. 
Moreover, TGF-β can directly down-regulate the expression of NKG2D, one of the 
most prominent activating natural killer (NK) cell receptors also conferring a co-
stimulatory signal to CD8+ T cells. Additionally, TGF-β decreases the expression of 
the NKG2D ligands MICA and ULBP2 on the tumor cell surface, further protecting 
glioma cells from immune-mediated destruction [77, 78]. TGF-β can polarize myeloid 
compartment cells into a M2 pro-tumorigenic phenotype, and impair antigen 
presentation by DC [79, 80]. Importantly, other TGF-β super-family members, such 
as GDF-15, also exert immune evasive effects in experimental gliomas [81]. Because 
of its strong immunosuppressive properties as well as further effects contributing to 
the malignant phenotype of glioma cells such as increased migration and invasion, 
angiogenesis, proliferation and maintenance of the stem-cell phenotype, TGF-β has 
been regarded an attractive therapeutic target [82-86]. However, despite many 
promising results in pre-clinical models, translation of TGF-β inhibition into clinical 
practice has remained challenging and a phase II trial in patients with recurrent GBM 
using the serine/threonine kinase inhibitor galunisertib, which blocks the intracellular 
cascade signalling initiated by TGF-β ligands through TGFβRI,  did not improve 
progression-free or overall survival [45, 87-90]. It remains to be determined whether 
other strategies aiming at inhibiting TGF-β activity translate into clinical benefit or 
whether TGF-β inhibition alone is insufficient to mount significant anti-tumor immune 
responses. 
Beyond TGF-β, many other glioma cell-secreted factors have been discovered. It has 
been shown that VEGF it is not only involved in glioma angiogenesis but can also 
hamper the maturation and function of APC and induce the expression of inhibiting 
receptors, such as PD-1 and CTLA-4,  on CD8+ T cells, negatively regulating their 
effector activity in the tumor microenvironment [91, 92]. Other factors and cytokines 
12 
 
with immunosuppressive functions released by glioma cells are IL-10, regeneration 
and tolerance factor (RTF), CSF-1, NO, prostaglandin E-2 (PGE-2) and arginase I. 
IL-10 may induce the expression of PD-L1 on monocytes while RTF may protect 
glioma cells from NK cell-mediated killing as shown in preclinical models [93, 94]. 
Levels of arginase I in the serum have been associated with immunosuppression in 
GBM patients whereas adult neural stem/progenitor cells-derived NO can suppress T 
cell function along with PGE-2 [95, 96]. Notably, the expression of some of these 
glioma-secreted factors may be upregulated following standard therapy treatment 
[97] which must be considered when designing future trials that combine 
conventional therapies with novel immunotherapeutic approaches [98].  
 
3.3 Glioma cell membrane-bound factors with immunosuppressive function 
 
Glioma cells can inhibit immune responses by direct cell-cell interactions involving 
several cell membrane-bound factors. One of the best characterized inhibitory 
pathways is represented by the axis formed by PD-L1, present on the tumor cell 
surface, and its cognate receptor PD-1 found on activated T cells. PD-1 plays a key 
role as immunological “rheostat”, dampening immune cell reactivity and maintaining 
immunological tolerance [99]. When bound to its ligands, PD-L1 or PD-L2, the SH2-
domain containing tyrosine phosphatase (SHP)-2 protein is recruited in proximity of 
the antigen receptor signalling complex where it impedes the downstream activation 
pathway and induces exhaustion [100]. Thus, PD-L1-expressing tumors can generate 
a barrier against cytotoxic T cells in a protective process termed “molecular shield” 
[101]. Paramount importance of this axis has been demonstrated by durable and 
unprecedented clinical responses achieved by blocking PD-1 signalling with 
monoclonal antibodies in tumors such as metastatic melanoma and non-small cell 
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lung cancer [7, 102]. Although the activity of anti-PD1 antibodies against tumors 
residing in the brain is yet to be determined, these promising results and long-lasting 
responses prompted clinical evaluation of PD-1 inhibitors also in the context of newly 
diagnosed and recurrent glioblastoma [103, 104]. 
At the molecular level, the two ligands have a different expression pattern. PD-L1 is 
ubiquitously expressed and studies on its promoter revealed that two IFN regulatory 
factor (IRF)-1 binding sites exist. In GBM, the common phosphatase and tensin 
homolog (PTEN) loss has been linked with increased post-transcriptional expression 
of PD-L1. Conversely, PD-L2 expression is restricted to few activated immune cell 
populations and some tumor cell types but not glioblastoma [99, 105]. Several 
studies have proven the expression of PD-L1 in glioma cells in vitro and in vivo [106-
110]. PD-L1 levels are dramatically increased in the presence of IFN-γ, one of the 
master immune effector cytokines. This process is called adaptive resistance and its 
physiological function is to secure the integrity of normal tissue during inflammation. 
Tumors hijack this system to escape from immune recognition and attack [111]. 
Striking survival benefits and even complete tumor eradication have been achieved in 
pre-clinical glioma models using PD-1 blockade either alone or in combination with 
radiotherapy or other immune checkpoint inhibitors [112-114]. Although these results 
highlight the potential importance of this pathway in the immunobiology of gliomas, 
the value of PD-L1 expression as a clinical prognostic factor as well as its use as 
biomarker for response to treatment with a PD-1 inhibitor remain controversial. 
Importantly, this ligand is not only present on tumor cells but can be virtually 
expressed by all cell types residing in the tumor microenvironment. For example, an 
immunosuppressive state can be induced by TAM through PD-L1 action [93]. 
Furthermore, an IFN-β-mediated autocrine loop increases the expression of PD-L1 in 
neurons and has been linked with glioma cell death induction and prolonged survival 
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of glioma patients [115]. PD-L1 may also confer reverse signalling into the tumor cell 
promoting resistance to apoptotic stimuli and may thereby be involved in the 
regulation of glucose metabolism [101, 116]. Hence, this ligand may represent a 
crucial cancer-promoting hub active during both tumor onset and subsequent 
immune escape and persistence.  
Another molecule present on the cell surface of glioma cells is CD95 (Fas) ligand. 
This molecule can protect tumor cells from immune cell attack by inducing apoptosis 
in tumor-infiltrating lymphocytes following binding to its receptor on T cells [117-119]. 
Promising data in pre-clinical models prompted further investigation in human 
patients. APG101, a CD95 ligand binding fusion protein, has been evaluated in a 
randomized phase II trial in GBM patients with first or second tumor recurrence 
yielding promising results [120]. 
Glioma cells can also express non-classical major histocompatibility complex (MHC) 
class I molecules and directly inhibit immune cells. In GBM, HLA-E and HLA-G are 
mediators of glioma-induced immune cell inhibition. HLA-E is expressed by long-term 
and glioma-initiating tumor cells and inhibits NKG2D-mediated immune cell killing 
[121, 122]. Similarly, HLA-G expression interferes with efficient T cell priming and 
protects glioma cells from alloreactive and antigen-specific killing. Intriguingly, few 
HLA-G-positive cells within a HLA-G negative population were enough to exert 
significant immunosuppression in vitro [123]. Another molecule that represses NK cell 
activity against glioma cells is lectin-like transcript-1 (LLT-1), a ligand for the inhibitory 
NK cell receptor CD161. LLT-1 is expressed by glioma cells and is further induced by 
TGF-β. Silencing of this ligand restored in vitro NK cell-mediated killing of glioma 
cells [124]. 
 
3.4 Tumor cell metabolism 
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In normal cells, glucose is metabolized into pyruvate, which then enters the 
mitochondria as substrate to generate ATP through the process of oxidative 
phosphorylation. Conversely, most cancer cells produce energy by fermenting 
glucose into lactate, which exerts pleiotropic effects on the tumor microenvironment. 
It inhibits anti-tumor immune cell reactivity by several means including the inhibition 
of NK cell activity via down-regulation of perforin and granzyme B expression as well 
as an increased recruitment of bone marrow-derived MDSC. Furthermore, it impairs 
T cell activation and killing [125, 126] . Similarly, lactate dehydrogenase, which 
catalyses the reversible conversion of pyruvate into lactate, is highly expressed in 
hypoxic tumor regions thereby fostering immune evasion through NKG2D ligand 
induction in tumor-infiltrating myeloid cells and circulating monocytes [127].  
Probably the most important metabolic pathway in glioma cells contributing to the 
immunosuppressive microenvironment is tryptophan catabolism. Tryptophan is an 
essential amino acid that can be metabolized into kynurenine by indoleamine-2,3-
dioxygenase (IDO). Glioma cells express IDO which depletes tryptophan. Both 
tryptophan shortage as well as the production of kynurenine and similar catabolites 
can induce T cell anergy and immune cell apoptosis [128, 129]. IDO expression is 
associated with poor prognosis in GBM and expression of IDO in glioma cells 
resulted in increased Treg recruitment to the tumor in a preclinical animal model. In 
contrast, IDO-deficient tumor cells were efficiently eradicated by the immune system 
[130]. IDO has therefore been regarded as a promising therapeutic target. However, 
a challenge linked to IDO targeting is the presence of two other enzymes which may 
compensate its function: IDO2 and tryptophan-2,3-dioxygenase (TDO). Particularly, 
kynurenine produced by TDO may contribute to tumor cell survival and suppresses 
anti-tumor immune responses through the activation of the aryl hydrocarbon receptor 
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(AHR) signalling pathway. The TDO-AHR axis was found to be active also in human 
brain tumors such as glioblastoma and linked to poor survival [131].  
 
4. Conclusions and outlook 
 
Glioblastoma is paradigmatic for its ability to interfere with anti-tumor immune 
reactivity. In a comprehensive analysis using large-scale genomic datasets of 
different tumor entities, Rooney et al demonstrated that GBM has the lowest “immune 
cytolytic activity” amongst all neoplasias [132]. Yet, the immune cytolytic activity in 
GBM is higher than in low-grade gliomas and normal brain tissue, suggesting that 
there is an interaction between the immune system and the tumor cells.  
GBM imposes a tight local immunosuppressive network by virtue of an intertwined 
assembly of immunosuppressive mechanisms (Figure 2). T cell priming, activation 
and killing, is restrained in a paracrine-fashion through secretion of TGF-β and other 
soluble molecules, and by direct cell-cell contacts involving PD-L1, CD95-L or non-
classical MHC class-I proteins. Treg and MDSC cells are recruited to dampen anti-
tumor immune activity and macrophages as well as neutrophils are skewed toward a 
tumor-promoting phenotype. The tumor mass is associated with a detrimental 
hypoxic environment which may further support malignant clonal selection and 
immune impairment. Aberrant metabolic pathways withdraw key nutrients such as 
glucose and tryptophan, and result in immunosuppressive metabolites leading to T 
cell anergy and apoptosis. Looking at this complex situation, it becomes clear that 
exploiting the immune system for therapeutic purposes may require therapeutic 
combinations aiming at blocking major GBM-derived inhibitory hubs as well as a re-
invigoration of innate and adaptive immune reactions by additional measures such as 
vaccination. Possibly, it will even be required to apply ex vivo manipulation of 
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immune cells and subsequent re-infusion to patients. Some of these concepts are 
currently being explored in a therapeutic approach involving chimeric antigen 
receptor (CAR) cell technology. Here, naïve T cells are transduced with a construct 
expressing a receptor for a specific antigen. T cells bearing a CAR can be activated 
by this antigen in the absence of any co-stimulation. The recognized antigen should 
ideally be expressed exclusively by tumor cells to avoid any collateral damage to 
normal tissues. Currently, phase I/II clinical trials are exploiting CAR T cells targeting 
the glioma-specific antigens EGFRvIII and IL13Rα2 (NCT02209376; NCT01082926), 
which have demonstrated promising results in preclinical models [133, 134]. Further 
clinical strategies and challenges associated with these immunotherapeutic 
approaches have been reviewed elsewhere [104, 135, 136]. From the therapeutic 
perspective, improvement of drug delivery across the BBB may also be crucial to 
increase the efficacy of immunological treatments. Finally, a deeper understanding of 
the immunological routes from the periphery to the brain may allow for the design of 
new therapeutic targets and strategies.   
So far, immunotherapy for brain tumors has been largely disappointing. However, in 
light of the increased knowledge on tumor-derived immunosuppressive pathways as 
well as the availability of novel drugs such as vaccines and checkpoint inhibitors, a 
reappraisal of the available and potentially useful immunotherapeutic approaches is 
warranted (Figure 3). Well-designed clinical trials accompanied by appropriate 
translational research efforts aiming at understanding which patients may benefit 
from immunotherapeutic treatment may result in clinical progress in the near future.  
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Figure 1. Glioma cell-derived secreted factors. Glioma cells can release several 
soluble mediators which exert a variety of immunosuppressive effects. Transforming 
growth factor (TGF)-β inhibits transcription of IFN-γ, granzyme B (GZMB) and 
NKG2D in immune effector cells, induces the alternative activation of macrophages 
(M2) and mediates regulatory T cell (TREG) induction and recruitment from the 
periphery. Vascular endothelial growth factor (VEGF) impairs the antigen-
presentation capacity of dendritic cells and increases the expression of immune 
inhibitory checkpoint molecules on the surface of T effector cells, such as 
programmed cell death (PD)-1. Growth and differentiation factor (GDF)-15, IL-10, 
regeneration and tolerance factor (RTF), colony stimulating factor (CSF)-1, nitric 
oxide (NO), prostaglandin E-2 (PGE-2) and arginase I (ArgI) generate an 
immunosuppressive environment which hampers anti-tumor immune activity.  
 
Figure 2. Cellular and molecular pathways of immunosuppression. Regulatory T 
cells (TREG) and alternatively activated macrophages (M2) and neutrophils (N2) 
interfere with the anti-tumor activity of natural killer (NK) and cytotoxic T cells (A). 
IFN-γ secreted by T cells to kill tumor cells can induce the expression of programmed 
cell death ligand (PD-L)1. This ligand binds its cognate receptor programmed cell 
death (PD)-1 expressed on activated T cells ultimately leading to T cell anergy and 
apoptosis. PD-L1 can also be expressed on myeloid-derived suppressor cells 
(MDSC) that are recruited to hypoxic regions of the tumor (B). The essential amino 
acid tryptophan (L-Trp) is crucial for proper T cell activation and effector function. 
Glioma cells express the enzymes indoleamine-2,3-dioxygenase (IDO) and 
tryptophan-2,3-dioxygenase (TDO) which can consume this amino acid restricting T 
cell metabolism. Kynurenine (Kyn), a catabolic product of L-Trp metabolism, is toxic 
for T cells and binds to the aryl hydrocarbon receptor (Ahr) mediating tumor cell 
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survival (C). Non-classical MHC class-I molecules such as HLA-E and HLA-G as well 
as lectin-like transcript-1 (LLT-1) are expressed on the tumor cell surface and 
mediate glioma cell immune-evasion (D).  
 
Figure 3. Therapeutic targeting of the immunosuppressive microenvironment. 
Alternatively activated macrophages (M2) activity could be reversed by colony 
stimulating factor 1 receptor (CSF-1R) inhibitors, whereas regulatory T cells (TREG) 
are depleted by treatment with antibodies targeting CD25. VEGF effects on tumor 
vasculature and immune cells may be blocked by the monoclonal antibody 
bevacizumab. Small molecules targeting the TGF-β receptor 1 (TGFβRI) can relieve 
the immunosuppressive effects exerted by TGF-β on T cells and prevent its tumor 
cell-intrinsic pro-tumorigenic functions. Antibodies targeting PD-1 or its ligand PD-L1 
may reinvigorate exhausted T cells restoring their activity against tumor cells. 1-
methyl-D-tryptophan (1-D-MT) is an indoleamine-2,3-dioxygenase (IDO) inhibitor 
which may exert anti-tumor effects in combination with a chemotherapeutic agent.  
 
